Study identification

EU PAS number

EUPAS1000000740

Study ID

1000000740

Official title and acronym

Metamizole and Acute Kidney Injury (M-AKI)

DARWIN EU® study

No

Study countries

Netherlands

Study description

Herein, a retrospective cohort study using electronic health records (EHR) from a major Dutch academic hospital (Amsterdam UMC) is conducted to assess the kidney safety profile of metamizole (dipyrone) use.
For this, adult inpatients (target population) who have undergone a recent surgery (postoperative setting) are selected.
The assigned treatment strategies (metamizole; active comparators: opioids, NSAIDs) are investigated to test a potential causal link between metamizole and acute kidney injury characterised by a set of predefined estimands.

Study status

Ongoing
Research institutions and networks

Institutions

Amsterdam UMC
First published:
01/02/2024
Institution Educational Institution Hospital/Clinic/Other health care facility

Contact details

Daniel Fernández Llaneza 0000-0002-2770-4214

Primary lead investigator
ORCID number:
0000-0002-2770-4214

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:
Actual:

Date of final study report

Planned:
Sources of funding
Other public funding (e.g. hospital or university)

More details on funding

This work was supported by Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO; Dutch Research Council) [KICH1.ST01.20.011] and co-funded in-cash by Dutch Kidney Foundation and National Intensive Care Evaluation (NICE) foundation, and in-kind by PHARMO Institute for Drug Outcomes Research, Castor, InsightRX, Z-Index, Digital Health Link.
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable